Prime medicine reports first quarter 2024 financial results and provides business updates

-- announced fda clearance of first-ever ind application for a prime editing product, pm359, for the treatment of cgd; initial data from planned phase 1/2 clinical trial expected in 2025 -- -- presented new preclinical data demonstrating broad potential of prime editing technology at lnp formulation and process development summit and asgct 2024 --
PRME Ratings Summary
PRME Quant Ranking